Bioequivalence Study for Donepezil Hydrochloride Tablets 10 mg Under Fed Condition
Primary Purpose
Healthy
Status
Completed
Phase
Phase 1
Locations
India
Study Type
Interventional
Intervention
Donepezil Hydrochloride
Aricept
Sponsored by
About this trial
This is an interventional treatment trial for Healthy focused on measuring Bioequivalence, Donepezil, crossover
Eligibility Criteria
Inclusion Criteria:
- Provide written informed consent.
- Must be healthy, adult, human beings within 18 and 45 years of age (both inclusive) weighing at least 50 kg.
- Having a body mass index between 18.0 and 24.9 (both inclusive), calculated as weight in Kg/height in m2.
- Must be of normal health as determined by medical history, physical examination and laboratory investigation performed within 28 days prior to the commencement of the study. (Laboratory values must be within normal limits or considered by the physician / investigator to be of no clinical significance).
Female Subjects
- Of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device (IUD), or abstinence.
- Surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject)
Exclusion Criteria:
- Incapable of understanding the informed consent.
- Systolic blood pressure less than 90 mm of Hg or more than 140 mm of Hg.
- Diastolic blood pressure less than 60 mm of Hg or more than 90 mm of Hg.
- Oral temperature is below 95.0°F or above 98.6°F.
- Pulse rate below 50/min or above 100/min.
- History of hypersensitivity or idiosyncratic reaction to investigational drug product or any other related drugs.
- Any evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal function.
- Consumption of grapefruit for the past ten days prior to the check-in, in each period.
- Regular smoker who has a habit of smoking more than nine cigarettes per day and has difficulty in abstaining from smoking during sample collection period.
- Habit of alcoholism and difficulty in abstaining from alcohol during the sample collection period.
- Difficulty in abstaining from xanthene containing food or beverages (like tea, coffee, chocolates and cola drinks) during the sample collection period.
- Intake of over the counter (OTC) or prescribed medications and enzyme modifying medication or systemic medication for the last 30 days before dosing.
- Clinically significant abnormalities and / or with significant diseases.
- Confirmed positive in alcohol screening.
- Confirmed positive in selected drug of abuse.
- Participated in any other clinical investigation using experimental drug/donated blood in past 90 days before the date of start of study.
- Confirmed positive in urine pregnancy test.
- Female detected to be pregnant, breast feeding or who is likely to become pregnant during the study.
Sites / Locations
- Bioserve Clinical Research Private Limited
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Donepezil Hydrochloride10 mg Tablets
Aricept 10 mg Tablets
Arm Description
Donepezil Hydrochloride 10 mg Tablets of Dr. Reddy's Laboratories Limited
Aricept 10 mgTablets of Pfizer Inc
Outcomes
Primary Outcome Measures
Area under curve (AUC)
Secondary Outcome Measures
Full Information
NCT ID
NCT01504516
First Posted
January 3, 2012
Last Updated
January 5, 2012
Sponsor
Dr. Reddy's Laboratories Limited
1. Study Identification
Unique Protocol Identification Number
NCT01504516
Brief Title
Bioequivalence Study for Donepezil Hydrochloride Tablets 10 mg Under Fed Condition
Official Title
Open Label, Balanced, Randomized, Two-treatment, Two-period, Two Sequence, Single Dose, Crossover, Oral Bioequivalence Study of Donepezil Hydrochloride Tablets 10mg With ARICEPT® (Containing Donepezil Hydrochloride) Tablets 10mg in Healthy, Adult, Human Subjects Under Fed Condition.
Study Type
Interventional
2. Study Status
Record Verification Date
September 2009
Overall Recruitment Status
Completed
Study Start Date
October 2009 (undefined)
Primary Completion Date
November 2009 (Actual)
Study Completion Date
December 2009 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Dr. Reddy's Laboratories Limited
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is an open label, balanced, randomized, two-treatment, two-period, two sequence, single dose, crossover, oral bioequivalence study.
Detailed Description
The study was an open label, balanced, randomized, two-treatment, two-period, two sequence,single dose, crossover, oral bioequivalence study of Donepezil Hydrochloride tablets 10mg of Dr. Reddy's Laboratories Limited, India comparing with that of ARICEPT® (containing Donepezil Hydrochloride) tablets 10mg of Pfizer Inc, New York, 10017 in healthy, adult, human subjects under fed condition. 28 subjects are enrolled in the study, 3 subjects are withdrawn from the study and 25 subjects are completed the study.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Healthy
Keywords
Bioequivalence, Donepezil, crossover
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
25 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Donepezil Hydrochloride10 mg Tablets
Arm Type
Experimental
Arm Description
Donepezil Hydrochloride 10 mg Tablets of Dr. Reddy's Laboratories Limited
Arm Title
Aricept 10 mg Tablets
Arm Type
Active Comparator
Arm Description
Aricept 10 mgTablets of Pfizer Inc
Intervention Type
Drug
Intervention Name(s)
Donepezil Hydrochloride
Other Intervention Name(s)
Aricept 10 mg
Intervention Description
Donepezil Hydrochloride Tablets 10 mg
Intervention Type
Drug
Intervention Name(s)
Aricept
Intervention Description
Aricept 10 mg Tablets
Primary Outcome Measure Information:
Title
Area under curve (AUC)
Time Frame
Pre-dose 0.5,0.75,1,1.5,2,2.5,3,3.5,4,4.5,5,5.5,6,7,8,9,10,12,16,24,36,48,72,96,120,144,168,192,216,240 and 264 hours post-dose
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Provide written informed consent.
Must be healthy, adult, human beings within 18 and 45 years of age (both inclusive) weighing at least 50 kg.
Having a body mass index between 18.0 and 24.9 (both inclusive), calculated as weight in Kg/height in m2.
Must be of normal health as determined by medical history, physical examination and laboratory investigation performed within 28 days prior to the commencement of the study. (Laboratory values must be within normal limits or considered by the physician / investigator to be of no clinical significance).
Female Subjects
Of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device (IUD), or abstinence.
Surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject)
Exclusion Criteria:
Incapable of understanding the informed consent.
Systolic blood pressure less than 90 mm of Hg or more than 140 mm of Hg.
Diastolic blood pressure less than 60 mm of Hg or more than 90 mm of Hg.
Oral temperature is below 95.0°F or above 98.6°F.
Pulse rate below 50/min or above 100/min.
History of hypersensitivity or idiosyncratic reaction to investigational drug product or any other related drugs.
Any evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal function.
Consumption of grapefruit for the past ten days prior to the check-in, in each period.
Regular smoker who has a habit of smoking more than nine cigarettes per day and has difficulty in abstaining from smoking during sample collection period.
Habit of alcoholism and difficulty in abstaining from alcohol during the sample collection period.
Difficulty in abstaining from xanthene containing food or beverages (like tea, coffee, chocolates and cola drinks) during the sample collection period.
Intake of over the counter (OTC) or prescribed medications and enzyme modifying medication or systemic medication for the last 30 days before dosing.
Clinically significant abnormalities and / or with significant diseases.
Confirmed positive in alcohol screening.
Confirmed positive in selected drug of abuse.
Participated in any other clinical investigation using experimental drug/donated blood in past 90 days before the date of start of study.
Confirmed positive in urine pregnancy test.
Female detected to be pregnant, breast feeding or who is likely to become pregnant during the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dr. L Krishna Murthy
Organizational Affiliation
Bioserve Clinical Research Private Limited
Official's Role
Principal Investigator
Facility Information:
Facility Name
Bioserve Clinical Research Private Limited
City
Hyderabad
State/Province
Andhra Pradesh
ZIP/Postal Code
500 037
Country
India
12. IPD Sharing Statement
Learn more about this trial
Bioequivalence Study for Donepezil Hydrochloride Tablets 10 mg Under Fed Condition
We'll reach out to this number within 24 hrs